Goldman Sachs Group Inc Morpho Sys Ag Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.6 - $18.18 $3.1 Million - $6.55 Million	360,079 Added 130.49%	636,016 $11.5 Million
Q4 2023 Feb 13, 2024	BUY	$4.55 - $9.9 $1.07 Million - $2.34 Million	236,171 Added 593.9%	275,937 $2.73 Million
Q3 2023 May 14, 2024	SELL	$6.72 - $8.6 $1.59 Million - $2.03 Million	-236,171 Reduced 85.59%	39,766 $267,000
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $65,627 - $83,987	9,766 Added 32.55%	39,766 $267,000
Q2 2023 May 14, 2024	SELL	$3.95 - $7.74 $1,576 - $3,088	-399 Reduced 1.31%	30,000 $224,000
Q2 2023 Aug 14, 2023	SELL	$3.95 - $7.74 $1,576 - $3,088	-399 Reduced 1.31%	30,000 $224,000
Q1 2023 May 14, 2024	BUY	$3.56 - $5.22 $1,420 - $2,082	399 Added 1.33%	30,399 $120,000
Q1 2023 May 11, 2023	BUY	$3.56 - $5.22 $1,420 - $2,082	399 Added 1.33%	30,399 $120,000
Q4 2022 May 14, 2024	SELL	$3.21 - $5.74 $41 - $74	-13 Reduced 0.04%	30,000 $107,000
Q4 2022 Feb 13, 2023	SELL	$3.21 - $5.74 $41 - $74	-13 Reduced 0.04%	30,000 $107,000
Q3 2022 May 14, 2024	BUY	$4.14 - $22.13 $53 - $287	13 Added 0.04%	30,013 $151,000
Q3 2022 Nov 10, 2022	BUY	$4.14 - $22.13 $53 - $287	13 Added 0.04%	30,013 $150,000
Q2 2022 May 14, 2024	SELL	$4.51 - $7.39 $1.11 Million - $1.82 Million	-245,937 Reduced 89.13%	30,000 $145,000
Q2 2022 Aug 15, 2022	SELL	$4.51 - $7.39 $28,913 - $47,377	-6,411 Reduced 17.61%	30,000 $145,000
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $26,303 - $43,600	-4,481 Reduced 10.96%	36,411 $247,000
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $86,959 - $119,233	9,577 Added 30.58%	40,892 $385,000
Q3 2021 Nov 10, 2021	BUY	$11.76 - $19.51 $368,264 - $610,955	31,315 New	31,315 $368,000

Others Institutions Holding MOR

# of Institutions

Shares Held

1.8M

Call Options Held

Put Options Held

14.7K

View Full List

About MorphoSys AG

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

More about MOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account